撒哈拉以南非洲HIV阳性局部晚期宫颈癌女性的顺铂联合放疗:艾滋病恶性肿瘤联盟的II期研究
该II期研究在撒哈拉以南非洲两个中心筛查64名HIV感染的局部晚期宫颈癌女性,40人入组,38人开始治疗,31人(82%)完成治疗。1年无进展生存率为76.3%(95%CI 59.4-86.9%),按入组分期无显著差异(p=0.581)。结论为多数HIV感染局部晚期宫颈癌女性可完成与HIV未感染女性相同顺铂剂量的同步放化疗,耐受性相当且抗逆转录病毒治疗依从性高。
要点
- 38名开始治疗者中31人(82%)完成同步放化疗。
- 1年无进展生存率76.3%(95%CI 59.4-86.9%),按分期无显著差异(p=0.581)。
- 最常见3或4级不良事件为淋巴细胞计数下降,影响所有接受治疗者。
核心结论
- 多数HIV感染的局部晚期宫颈癌女性可完成与HIV未感染女性相同顺铂剂量的同步放化疗,耐受性相当且治疗期间抗逆转录病毒治疗依从性高。
研究设计与样本
- 艾滋病恶性肿瘤联盟开展的II期研究,在撒哈拉以南非洲两个中心筛查64名HIV感染且未经治疗、组织学确诊的浸润性宫颈癌患者(FIGO IB2、IIA肿瘤>4 cm、IIB、IIIA、IIIB或IVA期),40名符合条件者入组,38名开始研究治疗。
- 受试者接受41.4-45 Gy体外放疗后行高剂量率近距离放疗,同步每周最多六次顺铂40 mg/m2,随访12个月。
主要发现
- 筛查64人,40名符合条件者入组,筛查比为1.60;38名开始治疗者中31人(82%)完成治疗。
- 至12个月随访时,7名女性死于疾病,31名完成治疗者中29人(94%)返回随访。
- 1年无进展生存率为76.3%(95%CI 59.4-86.9%),按入组分期无显著差异(p=0.581)。
- 参与者报告的抗逆转录病毒治疗依从性高;至12个月时,93%的参与者病毒载量检测不到。
- 最常见的3或4级不良事件为淋巴细胞计数下降,影响所有接受治疗者;非血液学严重不良事件与HIV未感染的局部晚期宫颈癌女性相似。
临床怎么用
- 作者结论认为多数HIV感染的局部晚期宫颈癌女性可完成与HIV未感染女性相同顺铂剂量的同步放化疗,耐受性相当且抗逆转录病毒治疗依从性高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). PATIENTS AND METHODS: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. RESULTS: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4-86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. CONCLUSIONS: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.
引用
- Einstein MH, Ndlovu N, Lee J, et al. Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium. Gynecol Oncol. 2019. PMID: 30773222. doi:10.1016/j.ygyno.2019.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。